AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
Bioxyne outpaces sector peers with performance in cannabis and health products
Paradigm Biopharmaceuticals secures convertible note funding for late-stage trial
Recce Pharmaceuticals and Botanix turn to debt as equity markets tighten
Biotech and healthcare stocks under the ASX 200 spotlight wrapped up the financial year with a surprising leader. Bioxyne Ltd (ASX:BXN), a player in the medicinal cannabis space, delivered standout performance, driven by gains in its diversified cannabis-based product range. Its operational footprint spans Australia and Europe, with products distributed via its Breathe Life Sciences subsidiary.
The company has reported strong momentum in revenue projections, supported by a broad portfolio that includes oils, flowers, and new-generation delivery formats. Bioxyne's performance stood in contrast to other cannabis-sector stocks, many of which saw subdued movement over the same period.
Amplia and Orthocell Rally on Clinical and Regulatory Milestones
Amplia Therapeutics (ASX:ATX) delivered notable results following data from a clinical trial in advanced pancreatic cancer, sparking increased attention toward its oncology pipeline. The results included a complete response in a subset of patients, which significantly elevated its visibility in the biotech community.
Orthocell Ltd (ASX:OCC) followed with strong gains after securing approval from the US Food and Drug Administration (FDA) for its nerve repair product, Remplir. This milestone expands the company's access to regulated markets, further advancing its commercialisation roadmap.
Convertible Notes and Structured Funding Rise Amid Equity Constraints
Paradigm Biopharmaceuticals Ltd (ASX:PAR) became one of several companies in the sector to shift toward non-equity financing structures. The company secured a convertible note facility from an international investment group, aimed at supporting its late-stage trial for a knee osteoarthritis therapy. The funding structure allows Paradigm to access capital in phases and extend its runway to a critical interim analysis stage.
Other companies followed similar paths. Recce Pharmaceuticals Ltd (ASX:RCE) announced a draw-down facility to support phase III trials targeting bacterial infections, while Botanix Pharmaceuticals Ltd (ASX:BOT) arranged a facility with a global investment firm to back the rollout of its dermatology treatment, Sofdra, in the US.
Grant and Government Funding Strengthen Local Innovation
Proteomics International Laboratories Ltd (ASX:PIQ) secured non-dilutive funding from national science infrastructure Bioplatforms Australia and the Western Australian Government. The capital will support development of a certified protein biomarker platform in partnership with a local university. Proteomics is active in diagnostic testing with current and future applications in diabetic kidney disease, endometriosis, and cancer-related biomarkers.
Mesoblast Reports Progress on FDA Alignment
Stem-cell company Mesoblast Ltd (ASX:MSB) reported ongoing discussions with the US FDA, indicating alignment on the regulatory requirements for its heart failure treatment, Revascor. The company expects to file an application for accelerated approval by year-end, following earlier regulatory success in paediatric graft-versus-host disease.
